Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

Inclusion criteria : * Male or female subjects, between 18 and 55 years of age, inclusive. * Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 28.0 kg/m\^2, inclusive. * Certified as healthy by a comprehensive clinical assessment. * Normal vital signs, electrocardiogram (ECG) and laboratory parameters. * Subject has to be willing to eat the standard radiolabelled meal (eggs on toasts and orange juice). Exclusion criteria: * Any history or presence of clinically relevant abnormalities at screening which could interfere with the objectives of the study or the safety of the subject's participation. * Blood donation of more than 450 mL within 3 months before inclusion. * History or presence of drug or alcohol abuse. * Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during the study. * If female, pregnancy (defined as positive beta-human chorionic gonadotropin \[β-HCG\] blood test), breast-feeding. * Any medication (including St John's Wort) within 14 days before inclusion with the exception of hormonal contraception or menopausal hormone replacement therapy. * Any subject in the exclusion period of a previous study: participation in a new chemical entity clinical study within the previous 3 months or a marketed drug clinical study within the previous 30 days. * Any subject who cannot be contacted in case of emergency. * Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab). * Positive result on urine drug screen. * Positive alcohol test. * Known hypersensitive to alginates, products or formulation excipients and/or to any component of the standardized meal. * Any subject with difficulty in chewing and/or swallowing. * Participation in a study in which radioisotopes were administered or in which subject was exposed to any radiation other than normal background radiation within the 12 months before the screening visit. * Any intake of aluminum and magnesium containing antacids or other alginate-containing medicinal products within 14 days before inclusion. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.